The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
Open accessAbstract
Summary: Aim : To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent Methods : This study was a 24‐week, double‐blind, multicentre trial following a 5‐week placebo run‐in period. One hundred and seventy‐five obese (body mass index (b.m.i.) ≥27 kg/m 2 ) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53.5 years; mean weight 99.3 kg) or placebo (n = 86; mean age 55 years; mean weight 98.2 kg) at 16 participating centres. To achieve moderate calorie restriction (deficit ≥ 250–500 kcal/day), individual dietary counselling was accompanied by either placebo or sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, and maintained at 20 mg through week 24). The main outcome measures included changes in weight, b.m.i., waist and hip circumference, glycaemic control, lipid profile, and quality of life, and evaluation of reported adverse events. Results : Sixty‐seven per cent of sibutramine patients and 71% of placebo patients completed the study. At week 24 when comparing those who completed the course, sibutramine compared with placebo patients showed significantly greater (p < 0.001) absolute (−4.3 vs. −0.4 kg) and percentage (−4.5% vs. −0.5%) weight loss. Weight loss ≥5% or 10% was achieved by 33% and 8% of sibutramine patients, respectively, but no placebo patients (p < 0.03 or better). Improvement in glycaemic control was correlated with weight loss (p < 0.001). In 5% and 10% weight‐loss responders, mean treatment differences were −0.53% and −1.65% (p ≤ 0.05), respectively, for HbA 1c , and −1.4 mmol/l (p ≤0.05) and −3.8 (p ≤0.05) mmol/l for fasting plasma glucose. Sibutramine patients also showed improvements in fasting insulin, triglycerides, HDL cholesterol, and quality‐of‐life assessments. Overall, sibutramine was well tolerated compared with the placebo. Sibutramine treatment was associated with small mean increases in blood pressure (BP) and pulse, although an increase in BP was not seen in sibutramine‐treated patients who lost ≥ 5% of their weight. Conclusions : Sibutramine produced statistically and clinically significant weight loss when used in combination with recommendations for moderate caloric restriction. This weight loss was associated with improvements in metabolic control and quality of life, and sibutramine was generally well tolerated in obese patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pharmacotherapy with the two currently approved drugs for obesity treatment, orlistat (a gastrointestinal lipase inhibitor) and sibutramine (a monoamine reuptake inhibitor), have both been associated with weight loss, improvements in serum lipids, and insulin sensitivity (76, 109, 270).”
From Cardiac remodeling in obesity (2008) · cites this paper as [109]
In the citing paper
“Orlistat treatment usually reduces blood pressure, while sibutramine is commonly associated with increased heart rate and blood pressure (109, 393).”
From Cardiac remodeling in obesity (2008) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,453
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Pouliot, M., Després, J., Lemieux, S., Moorjani, S., Bouchard, C., Tremblay, A., Nadeau, A., & Lupien, P. J. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90676-9 · Cited by 2,099
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Research works printed but not linked: 11
- Albu J, 1995, Weight control: metabolic and cardiovascular effects, Diabetes Rev, 3, 335
- Halford JCG, 1994, Effects in the rat of sibutramine on food intake and the behavioural satiety sequence [abstract], Br J Pharmacol, 114, 387P
- Heath MJ, 1999, Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus [abstract], Diabetes, 48, A308
- Olkin I, 1960, Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling. Stanford, CA.
- 10.2337/diab.35.2.155 · DOI
- 10.1001/archinte.148.4.873 · DOI
- Wynne RD, 1997, A single‐dose, placebo‐controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers, Int J Pharmaceut Med, 11, 65
- Goldstein DJ, 1992, Fluoxetine in obese patients with noninsulin‐dependent diabetes mellitus [abstract], Clin Res, 40, 240A
- Griffiths J, 1998, Sibutramine in the treatment of overweight non‐insulin dependent diabetics [abstract O72], Int J Obes Relat Metab Disord, 19, 41
- Griffiths J, 1995, Body composition changes following weight loss induced by sibutramine [abstract P395], Int J Obes Relat Metab Disord, 19, 144
- Yip I, 1998, Sibutramine reduces visceral fat, leptin, and estradiol level in obese women, FASEB, 12, A353
Cited by
Sorted by citations
Franz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.148 · Cited by 1,165
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Abel, E. D., Litwin, S. E., & Sweeney, G. (2008) · Physiological Reviews · doi:10.1152/physrev.00017.2007 · Cited by 736
“Orlistat treatment usually reduces blood pressure, while sibutramine is commonly associated with increased heart rate and blood pressure (109, 393).”
BackgroundMcTigue, K. M., Harris, R., Hemphill, B., Lux, L. J., Sutton, S. F., Bunton, A. J., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00013 · Cited by 599
“…82 Black: 12 Indian or Pakistani: 1 Mexican American: 2 Other: 3 Drug: 56 Placebo: 51 Drug: 45 Placebo: 46 Sibutramine: 35.1 kg/m2 Placebo: 35.5 kg/m2 Fujioka et al., 2000 (86) Titrated up to 20 mg/d D All participants: 250 to 500 kcal/d caloric deficit diet with individual dietary counseling 175…”
BackgroundInfluentialYanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 555
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Shekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L., & Gagné, J. (2003) · JAMA · doi:10.1001/jama.289.12.1537 · Cited by 511
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 451
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 490
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286
“In randomizedcontrolled trials of currently approved weight management agents in patients with type 2 diabetes, both orlistat, which inhibits intestinal lipases, and sibutramine, which inhibits monoamine reuptake, produced greater weight loss than placebo (14,15).”
BackgroundThe Efficacy and Safety of Sibutramine for Weight Loss
Arterburn, D. E., Crane, P. K., & Veenstra, D. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.994 · Cited by 255
Current and investigational antiobesity agents and obesity therapeutic treatment targets
Bays, H. E. (2004) · Obesity Research · doi:10.1038/oby.2004.151 · Cited by 228
Warkentin, L. M., Das, D., Majumdar, S. R., Johnson, J. A., & Padwal, R. S. (2013) · Obesity Reviews · doi:10.1111/obr.12113 · Cited by 206
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“…of 1.7 – 4.8 kg (1% – 5%), but with significantly more patients achieving the 5% and 10% weight loss threshold relative to placebo-treated controls (Fujioka et al., 2000; McMahon et al., 2000; Smith et al., 2001; Wooltorton, 2002; Yanovski and Yanovski, 2002; Hauner et al., 2004; Rucker et…”
BackgroundInfluentialCombating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Gaal, L. F. V. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 193
Pharmacotherapy for dyslipidaemia ? current therapies and future agents
Bays, H. E., & Stein, E. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1901 · Cited by 173
“Weight loss with sibutramine improves cardiovascular risk factors such as lipid blood levels [223] and glucose control [187-189].”
BackgroundPharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 169
“In a 24-week trial, the dose of sibutramine was increased from 5 to 20 mg/day over 6 weeks (Fujioka et al., 2000).”
BackgroundMcNulty, S., Ur, E., & Williams, G. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.125 · Cited by 167
“Sibutramine is generally well tolerated, although some patients show evidence of increased sympathetic cardiovascular tone, with mild tachycardia and rises in blood pressure (12,13).”
Gummesson, A., Nyman, E., Knutsson, M., & Karpefors, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12971 · Cited by 162
Hanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151
Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E. W., Schmid, C. H., Kim, C., & Lau, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1395 · Cited by 146
“We found no significant blood pressure increase with sibutramine; however, only 3 studies reported this outcome.(45,46,48) Concerns have been raised about the safety of sibutramine after review of postmarketing data.”
BackgroundMethodManagement of Obesity as a Chronic Disease: Nonpharmacologic, Pharmacologic, and Surgical Options
Fujioka, K. (2002) · Obesity Research · doi:10.1038/oby.2002.204 · Cited by 146
Self-citationCarbonic anhydrase inhibitors in the treatment and prophylaxis of obesity
Supuran, C. T. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1545 · Cited by 141
“Sibutramine is devoid of amphetaminelike abuse potential [3] and leads to weight losses of > 10% in nearly 33% of patients treated for 6 months to 1 year [8].”
BackgroundRatner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · Europe PMC (PubMed Central) · Cited by 129
Obesity: A Review of Pathogenesis and Management Strategies
Kaila, B., & Raman, M. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/609039 · Cited by 129
Maciejewski, M. L., Patrick, D. L., & Williamson, D. F. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.015 · Cited by 127
The discovery and status of sibutramine as an anti-obesity drug
Luque, C. A., & Rey, J. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01423-1 · Cited by 128
A new evidence‐based model for weight management in primary care: the Counterweight Programme
The Counterweight Project Team (2004) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2004.00517.x · Cited by 124
Long-term effects of weight-reducing diets in hypertensive patients
Siebenhofer, A., Jeitler, K., Berghold, A., Waltering, A., Hemkens, L. G., Semlitsch, T., Pachler, C., Strametz, R., & Horvath, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008274.pub2 · Cited by 121
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N. A. S., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 118
Treatment of obesity: an update on anti‐obesity medications
Halpern, A., & Mancini, M. C. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00083.x · Cited by 115
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Treatment of overweight and obesity: Lifestyle, pharmacologic, and surgical options
Cannon, C. P., & Kumar, A. (2009) · Clinical cornerstone · doi:10.1016/s1098-3597(09)80005-7 · Cited by 116
Berne, C., & the Orlistat Swedish Type 2 diabetes Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01474.x · Cited by 112
Self-citationMcMahon, F. G., Weinstein, S. P., Rowe, E., Ernst, K. R., Johnson, F., & Fujioka, K. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001298 · Cited by 105
Self-citationEffect of Sibutramine on Weight Loss and Blood Pressure: A Meta‐analysis of Controlled Trials
Kim, S. H., Lee, Y., Jee, S. H., & Nam, C. M. (2003) · Obesity Research · doi:10.1038/oby.2003.152 · Cited by 106
Bray, G. A. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1011808701117 · Cited by 105
Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes
Vettor, R., Serra, R., Fabris, R., Pagano, C., & Federspil, G. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.942 · Cited by 103
Effects of Sibutramine in Obese Female Subjects With Type 2 Diabetes and Poor Blood Glucose Control
Gökçel, A., Karakose, H., Ertörer, M. E., Tanaci, N., Tütüncü, N. B., & Guvener, N. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1957 · Cited by 100
Shikora, S. A., Toouli, J., Herrera, M. F., Kulseng, B. E., Zulewski, H., Brancatisano, R., Kow, L., Pantoja, J. P., Johnsen, G., Brancatisano, A., et al. (2013) · Journal of Obesity · doi:10.1155/2013/245683 · Cited by 101
Weight management and current options in pharmacotherapy: Orlistat and sibutramine
Leung, W. Y. S., Thomas, G. N., Chan, J. C. N., & Tomlinson, B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90009-9 · Cited by 98
Kopelman, P. G., de Groot, H. G., Rissanen, A., Rössner, S., Toubro, S., Palmer, R., Hallam, R., Bryson, A. L., & Hickling, R. I. (2009) · Obesity · doi:10.1038/oby.2009.155 · Cited by 93
Current Management Strategies for Coexisting Diabetes Mellitus and Obesity
Scheen, A. J. (2003) · Drugs · doi:10.2165/00003495-200363120-00001 · Cited by 93
The use of sibutramine in the management of obesity and related disorders: An update
Tzotzas, T., Krassas, Τζιόμαλος, Κ., & Jones, A. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4027 · Cited by 88
Liquid Meal Replacements and Glycemic Control in Obese Type 2 Diabetes Patients
Yip, I., Go, V. L. W., DeShields, S., Saltsman, P., Bellman, M., Thames, G., Murray, S. P. L., Wang, H., Elashoff, R. M., & Heber, D. (2001) · Obesity Research · doi:10.1038/oby.2001.140 · Cited by 86
A review of the metabolic effects of sibutramine
Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x38132 · Cited by 84
“Furthermore, Fujioka et al.24 determined the efficacy of sibutramine treatment for 6 months in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent.”
BackgroundPharmacological and surgical treatment of obesity.
Shekelle, P., Morton, S. C., Maglione, M., Suttorp, M. J., Tu, W., Li, Z., Maggard, M. A., Mojica, W., Shugarman, L. R., & Solomon, V. (2004) · PubMed · Cited by 80
5‐Hydroxytryptamine Medications for the Treatment of Obesity
Burke, L. K., & Heisler, L. K. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12287 · Cited by 82
Wolf, A. M., Siadaty, M., Yaeger, B., Conaway, M. R., Crowther, J. Q., Nadler, J. L., & Bovbjerg, V. E. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.05.015 · Cited by 79
Sibutramine‐associated adverse effects: a practical guide for its safe use
Florentin, M., Liberopoulos, E. N., & Elisaf, M. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00425.x · Cited by 78
“In some studies, BP increases were reported following sibutramine administration, both in patients with (28,52) and without (28,53) pre-existing hypertension.”
Sramek, J. J., Leibowitz, M. T., Weinstein, S. P., Rowe, E., Mendel, C. M., Levy, B., McMahon, F. G., Mullican, W. S., Toth, P. D., & Cutler, N. R. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001299 · Cited by 79
Self-citationCardiovascular outcome trials in obesity: A review
Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews · doi:10.1111/obr.13112 · Cited by 75
“Sibutramine (20 mg; now withdrawn) also improved HbA1c, HDL-C and triglycerides in a placebo-controlled double-blind trial.(34) In the XENDOS trial, orlistat 120 mg, compared with placebo, improved waist circumfer-”
BackgroundOne-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes
Redmon, J. B., Raatz, S. K., Reck, K. P., Swanson, J. E., Kwong, C. A., Fan, Q., Thomas, W. T. B., & Bantle, J. P. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2505 · Cited by 77
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 81
“In all these trials weight loss is associated with improved lipid profiles [41, 42, 44]; however, the data for blood pressure has been conflicting.”
Pharmacological treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200024 · Cited by 73
Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction
Lee, M., & Aronne, L. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.007 · Cited by 73
Combining Behavioral and Pharmacological Treatments for Obesity
Phelan, S., & Wadden, T. A. (2002) · Obesity Research · doi:10.1038/oby.2002.77 · Cited by 73
Finer, N. (2002) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2002.0231 · Cited by 71
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Ashtary‐Larky, D., Ghanavati, M., Lamuchi-Deli, N., Payami, S. A., Alavi-Rad, S., Boustaninejad, M., Afrisham, R., Abbasnezhad, A., & Alipour, M. (2017) · Intern J Endocrinol Metab · doi:10.5812/ijem.13249 · Cited by 73
“Consistent with the current study, several studies did not support the impact of WL on blood pressure in people, who had normal blood pressure (16, 28).”
ResultLow Weight and Overweightness in Older Adults: Risk and Clinical Management
Jahangir, E., Schutter, A. D., & Lavie, C. J. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.01.001 · Cited by 67
Torquati, A., Wright, K., Melvin, W. V., & Richards, W. O. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.038 · Cited by 66
The investigation and management of obesity
Labib, M. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.56.1.17 · Cited by 65
Effects of two weight-loss diets on health-related quality of life
Yancy, W. S., Almirall, D., Maciejewski, M. L., Kolotkin, R. L., McDuffie, J. R., & Westman, E. C. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9444-8 · Cited by 67
“but HRQOL improved more only in the General Health domain [31].”
BackgroundGreenway, F. L., & Caruso, M. K. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1083 · Cited by 62
Kaukua, J., Pekkarinen, T., & Rissanen, A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802591 · Cited by 60
A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
Nisoli, E., & Carruba, M. O. (2003) · Drug Safety · doi:10.2165/00002018-200326140-00004 · Cited by 58
Benefits of moderate weight loss in patients with type 2 diabetes
Fujioka, K. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01155.x · Cited by 56
Self-citationZhou, X., Ji, L., Ran, X., Su, B., Ji, Q., Pan, C., Weng, J., Ma, C., Hao, C., Zhang, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0144179 · Cited by 56
“Our findings confirm the negative impact of obesity on achieving 3B treatment goals, and that the negative effects were not offset by pharmacotherapy, emphasizing the known benefit of weight loss in diabetes patients [26,27].”
ResultThe management of the obese diabetic patient
Albu, J., & Raja-Khan, N. T. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00043-5 · Cited by 56
“The decreases in HgbAic and fasting plasma glucose correlated with the amount of weight loss [101].”
BackgroundInfluentialObesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.
Wooltorton, E. (2002) · Europe PMC (PubMed Central) · Cited by 55
Metabolic Syndrome: Treatment of Hypertensive Patients
Israili, Z. H., Lyoussi, B., Hernández-Hernández, R., & Velasco, M. (2007) · American Journal of Therapeutics · doi:10.1097/01.pap.0000249936.05650.0c · Cited by 53
Wang, Z., Sun, J., Han, R., Fan, D., Dong, X., Luan, Z., Xiang, R., Zhao, M., & Yang, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13047 · Cited by 59
“cells, probably by reducing insulin resistance, which is beneficial for enhancing glycaemic control.(45) This meta-analysis showed that, compared to control groups, groups treated with SGLT-2is showed significant weight loss.”
ResultAdiposopathy is a more rational treatment target for metabolic disease than obesity alone
Bays, H. E., & Dujovne, C. A. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0052-6 · Cited by 51
Long-term effects of weight-reducing drugs in hypertensive patients
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub3 · Cited by 51
Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes
Redmon, J. B., Reck, K. P., Raatz, S. K., Swanson, J. E., Kwong, C. A., Ji, H., Thomas, W., & Bantle, J. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1311 · Cited by 66
“5% but had only modest effects on HbA1c in two studies (9,10) and, at a dose of 15 mg daily, produced weight loss of 5.”
BackgroundTratamento Farmacológico da Obesidade
Mancini, M. C., & Halpern, A. (2002) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302002000500003 · Cited by 49
Scheen, A. J., & Ernest, P. (2002) · PubMed · Cited by 49
Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats
Hayashi, A., Sonoda, R., Kimura, Y., Takasu, T., Suzuki, M., Sasamata, M., & Miyata, K. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.032 · Cited by 48
Agonist diversity in 5-HT2C receptor-mediated weight control in rats
Hayashi, A., Suzuki, M., Sasamata, M., & Miyata, K. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2019-z · Cited by 45
“However, current marketed antiobesity agents are known to have side effects such that sibutramine is known to have cardiovascular side effects and orlistat has a gastrointestinal effects (Fujioka et al. 2000; McMahon et al. 2000; Leung et al. 2003).”
BackgroundObesity and pharmacologic therapy
Thearle, M. S., & Aronne, L. J. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00066-5 · Cited by 45
“In addition, 30% of patients lost more than 10% of their body weight compared with only 6% of patients in the placebo-treated groups [16,17,19,23–25].”
BackgroundInfluentialObesity: A Review of Pathogenesis and Management Strategies in Adult
Aktar, N., Qureshi, N. K., & Ferdous, H. S. (2017) · Delta Medical College Journal · doi:10.3329/dmcj.v5i1.31436 · Cited by 49
Obesity and diabetes mellitus in the Arab world
Alzaman, N. S., & Ali, A. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.03.009 · Cited by 43
Sibutramine and the management of obesity
Poston, W. S. C., & Foreyt, J. P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.3.633 · Cited by 41
“[43] evaluated the use of sibutramine with 175 obese poorly controlled Type 2 diabetics in a 24-week, double-blind, multi-centre trial after a 5-week placebo run-in.”
BackgroundMethodInfluentialReduction of body weight and co‐morbidities by orlistat: The XXL – Primary Health Care Trial
Wirth, A. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00428.x · Cited by 39
Sabherwal, S., Bravis, V., & Devendra, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02372.x · Cited by 38
Sibutramine: Balancing weight loss benefit and possible cardiovascular risk
SIMONE, G. D., & D’Addeo, G. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.03.008 · Cited by 36
Long‐Term Pharmacotherapy for Obesity
Klein, S. (2004) · Obesity Research · doi:10.1038/oby.2004.283 · Cited by 35
Sánchez‐Reyes, L., Fanghänel, G., YAMAMOTO, J., MARTINEZRIVAS, L., Campos-Franco, E., & Berber, A. C. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.017 · Cited by 35
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Dolovich, L., & Houlden, R. L. (2012) · Europe PMC (PubMed Central) · Cited by 33
Tambascia, M. A., Geloneze, B., Repetto, E. M., Geloneze, S. R., Picolo, M., & Magro, D. O. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00285.x · Cited by 34
Lloret‐Linares, C., Greenfield, J. R., & Czernichow, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02550.x · Cited by 36
Recomendaciones y algoritmo de tratamiento del sobrepeso y la obesidad en personas adultas
Arrizabalaga, J. J., Masmiquel, L., Vidal, J., Calañas-Continente, A., Díaz-Fernández, M. J., García‐Luna, P. P., Monereo, S., Moreiro, J., Moreno, B., Ricart, W., et al. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)74158-5 · Cited by 32
Qian, D., Zhang, T., Zheng, P., Liang, Z., Wang, S., Xie, J., Zhao, L., Zhang, Y., & Situ, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0482-5 · Cited by 33
Pharmacologic Treatment of Obesity
Sidhaye, A. R., & Cheskin, L. J. (2006) · KARGER eBooks · doi:10.1159/000090962 · Cited by 32
Metadata
- Authors
- Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S.
- Affiliations
- Scripps Health (US)
- The University of Texas Southwestern Medical Center (US)
- State University of New York (US)
- Corresponding author
- Fujioka, K.
- ORCID
- Fujioka, K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2000-05
- Volume
- 2
- Issue
- 3
- Pages
- 175-187
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2032907323
- Cited by
- 244
- References
- 42
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 3
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sibutramine, type 2 diabetes, obesity, weight loss, glycemic control, HbA1c, fasting blood glucose, lipid profile, quality of life, adverse events, appetite suppressants, nutrition counseling, caloric restriction, drug efficacy and tolerability, body mass index, waist and hip circumference
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Blood Pressure, Cyclobutanes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Female, Humans, Hyperglycemia, Lipids, Male, Middle Aged, Obesity, Quality of Life, Weight Loss, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
